# EDGAR Filing Document

**Accession Number:** 0001679628
**File Stem:** 0001493152-26-006711
**Filing Date:** 2026-2
**Character Count:** 44096
**Document Hash:** 5bb050b835a3181f5d75962b42380352
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-006711.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001493152-26-006711

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 38

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**EFFECTIVENESS DATE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JUPITER NEUROSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001679628
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474828381
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293466
- **FILM NUMBER:** 26633066

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 NORTH US HWY 1
- **STREET 2:** SUITE 504
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477
- **BUSINESS PHONE:** (561) 406-6154

**MAIL ADDRESS:**
- **STREET 1:** 1001 NORTH US HWY 1
- **STREET 2:** SUITE 504
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Jupiter Orphan Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20160713

As filed with the Securities and Exchange Commission on February 13, 2026

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**JUPITER NEUROSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **47-4828381** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **1001 North US HWY 1, Suite 504**<br> **Jupiter, FL**<br> (Address of Principal Executive Offices) | <br> **33477**<br> (Zip Code) |

---

**Jupiter Orphan Therapeutics, Inc. 2016 Equity Incentive Plan**

**Jupiter Orphan Therapeutics, Inc. 2021 Equity Incentive Plan**

**Jupiter Neurosciences, Inc. 2023 Equity Incentive Plan**

**Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan**

(Full title of the plan)

**Christer Rosén**

**Chief Executive Officer**

**Jupiter Neurosciences, Inc.**

**1001 North US HWY 1, Suite 504**

**Jupiter, Florida 33477**

**Telephone: (561) 406-6154**

(Name, address and telephone number, including area code, of agent for service)

Copy to:

---

| | |
|:---|:---|
| **Katherine E. Geddes**<br> **Reed Smith LLP**<br> **2850 N. Harwood Street, Suite 1500**<br> **Dallas, TX 75201**<br> **(469) 680-4220** | **Jeffrey G. Aromatorio, Esq.**<br> **Reed Smith LLP**<br> **225 Fifth Avenue**<br> **Pittsburgh, Pennsylvania 15222**<br> **(412) 288-3364** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐ Accelerated Filer ☐ <br> Non-Accelerated Filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the "Securities Act"), and the Note to Part I of Form S-8. The documents containing information specified in this Part I will be separately provided to the participants in the equity compensation plans covered by this Registration Statement, as specified by Rule 428(b)(1) under the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF DOCUMENTS BY REFERENCE** |

---

The following documents filed with the Securities and Exchange Commission (the "SEC") by Jupiter Neurosciences, Inc. (the "Registrant") are incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;(1) The
 Registrant's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1679628/000164117225001261/form10-k.htm) for the fiscal year ended December 31, 2024,
 filed with the SEC on March 28, 2025;

(2) The
 Registrant's Quarterly Reports on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on [May 15, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000164117225010990/form10-q.htm) , for the
 quarter ended June 30, 2025, filed with the SEC on [August 19, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000164117225024684/form10-q.htm) , and for the quarter ended September 30, 2025, filed with the
 SEC on [November 14, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000149315225023603/form10-q.htm) ;

(3) The
 Registrant's Current Reports on Form 8-K or Form 8-K/A filed with the SEC on [March 25, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000164117225000627/form8-k.htm) , [April 21, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000164117225005506/form8-k.htm) , [July 9, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000164117225018429/form8-k.htm) , [July 10, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000164117225018619/form8-k.htm) , [October 27, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000149315225019783/form8-k.htm) , [November 20, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000149315225024454/form8-ka.htm) , [December 22, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000149315225028789/form8-k.htm) , and [December 23, 2025](https://www.sec.gov/Archives/edgar/data/1679628/000149315225029124/form8-k.htm) , to the extent the information in such
 report is filed and not furnished; and

(4) The
 description of our capital stock contained in [Exhibit 4.1](https://www.sec.gov/Archives/edgar/data/1679628/000164117225001261/ex4-1.htm) to our Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1679628/000164117225001261/form10-k.htm) for the fiscal year ended December 31,
 2024, as filed with the SEC on March 28, 2025, and including any amendments and reports filed for the purpose of updating such description

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold, or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, that the Registrant may from time to time furnish to the SEC will be incorporated by reference into, or otherwise included in, this Registration Statement.

---

| | |
|:---|:---|
| **ITEM 4.** | **DESCRIPTION OF SECURITIES** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 5.** | **INTEREST OF NAMED EXPERTS AND COUNSEL** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 6.** | **INDEMNIFICATION OF DIRECTORS AND OFFICERS** |

---

Our certificate of incorporation provides that all of our directors, officers, employees and agents shall be entitled to be indemnified by us to the fullest extent permitted by the Delaware General Corporation Law (the "DGCL"). Section 145 of the DGCL concerning indemnification of officers, directors, employees and agents is set forth below.

Section 145. Indemnification of officers, directors, employees and agents; insurance.

&nbsp;&nbsp;&nbsp;&nbsp;(a) A
 corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened,
 pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by
 or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the
 corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
 partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts
 paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person
 acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation,
 and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person's conduct was unlawful.
 The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or
 its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person
 reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or
 proceeding, had reasonable cause to believe that the person's conduct was unlawful.

(b) A
 corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened,
 pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact
 that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
 as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses
 (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of
 such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the
 best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to
 which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery
 or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability
 but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which
 the Court of Chancery or such other court shall deem proper.

(c) To
 the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense
 of any action, suit or proceeding referred to in subsections (a) and (b) of this section, or in defense of any claim, issue or matter
 therein, such person shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by
 such person in connection therewith.

&nbsp;&nbsp;&nbsp;&nbsp;(d) Any
 indemnification under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only as
 authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or
 agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and
 (b) of this section. Such determination shall be made, with respect to a person who is a director or officer at the time of such
 determination, (1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than
 a quorum, or (2) by a committee of such directors designated by majority vote of such directors, even though less than a quorum,
 or (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion, or (4)
 by the stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;(e) Expenses
 (including attorneys' fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative
 action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding
 upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined
 that such person is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys'
 fees) incurred by former officers and directors or other employees and agents may be so paid upon such terms and conditions, if any,
 as the corporation deems appropriate.

(f) The
 indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not
 be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any
 bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person's official
 capacity and as to action in another capacity while holding such office. A right to indemnification or to advancement of expenses
 arising under a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to such
 provision after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative
 action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the
 time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.

(g) A
 corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee
 or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
 another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and
 incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the corporation
 would have the power to indemnify such person against such liability under this section.

(h) For
 purposes of this section, references to "the corporation" shall include, in addition to the resulting corporation, any
 constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
 existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that
 any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request
 of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
 or other enterprise, shall stand in the same position under this section with respect to the resulting or surviving corporation as
 such person would have with respect to such constituent corporation if its separate existence had continued.

&nbsp;&nbsp;&nbsp;&nbsp;(i) For
 purposes of this section, references to "other enterprises" shall include employee benefit plans; references to "fines"
 shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to "serving at
 the request of the corporation" shall include any service as a director, officer, employee or agent of the corporation which
 imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its
 participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the
 interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner "not opposed
 to the best interests of the corporation" as referred to in this section.

(j) The
 indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when
 authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the
 benefit of the heirs, executors and administrators of such a person.

(k) The
 Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification
 brought under this section or under any by law, agreement, vote of stockholders or disinterested directors, or otherwise. The Court
 of Chancery may summarily determine a corporation's obligation to advance expenses (including attorneys' fees).

Our certificate of incorporation also permits us to maintain insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification. We have purchased a policy of directors' and officers' liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.

These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

Any repeal or amendment of provisions of our certificate of incorporation affecting indemnification rights, whether by our board of directors, stockholders or by changes in applicable law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis, and will not in any way diminish or adversely affect any right or protection existing thereunder with respect to any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision.

The registrant also intends to enter into indemnification agreements with its future directors and executive officers. The registrant has purchased directors' and officers' liability insurance. The registrant believes that this insurance is necessary to attract and retain qualified directors and officers.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

---

| | |
|:---|:---|
| **ITEM 7.** | **EXEMPTION FROM REGISTRATION CLAIMED** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS** |

---

The following exhibits are hereby filed as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Description** |
| 4.1 | [Certificate of Incorporation of the Company dated December 30, 2015 (filed as Exhibit 3.1 to the Company's Registration Statement on Form S-1 filed with the SEC on October 12, 2021)](https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-1.htm) |
| 4.2 | [Certificate of Validation of the Company dated July 9, 2021 (including Certificate of Amendment to Certificate of Incorporation of the Company) (filed as Exhibit 3.2 to the Company's Registration Statement on Form S-1 filed with the SEC on October 12, 2021)](https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-2.htm) |
| 4.3 | [Certificate of Amendment to Certificate of Incorporation of the Company dated August 30, 2021 (filed as Exhibit 3.3 to the Company's Registration Statement on Form S-1 filed with the SEC on October 12, 2021)](https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-3.htm) |
| 4.4 | [Certificate of Amendment to Certificate of Incorporation of the Company dated November 19, 2021 (filed as Exhibit 3.4 to the Company's Registration Statement on Form S-1/A filed with the SEC on December 17, 2021)](https://www.sec.gov/Archives/edgar/data/1679628/000149315221031850/ex3-4.htm) |
| 4.5 | [Certificate of Amendment to Certificate of Incorporation of the Company dated January 25, 2022 (filed as Exhibit 3.5 to the Company's Registration Statement on Form S-1/A filed with the SEC on January 26, 2022)](https://www.sec.gov/Archives/edgar/data/1679628/000149315222002313/ex3-5.htm) |
| 4.6 | [Certificate of Amendment to Certificate of Incorporation of the Company dated June 14, 2024 (filed as Exhibit 3.6 to the Company's Registration Statement on Form S-1/A filed with the SEC on July 12, 2024)](https://www.sec.gov/Archives/edgar/data/1679628/000149315224027145/ex3-6.htm) |
| 4.7 | [Certificate of Amendment to Certificate of Incorporation of the Company dated December 19, 2025 (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on December 22, 2025)](https://www.sec.gov/Archives/edgar/data/1679628/000149315225028789/ex3-1.htm) |
| 4.8 | [Amended and Restated Bylaws (filed as Exhibit 3.4 to the Company's Registration Statement on Form S-1 filed with the SEC on October 12, 2021)](https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-4.htm) |
| 5.1 | [Opinion of Reed Smith LLP (filed herewith).](ex5-1.htm) |
| 23.1 | [Consent of Assurance Dimensions, LLC (filed herewith).](ex23-1.htm) |
| 23.2 | [Consent of Reed Smith LLP (reference is made to Exhibit 5.1).](ex5-1.htm) |
| 24.1 | [Power of Attorney (reference is made to the signature page hereto).](#poa_001) |
| 99.1 | [Jupiter Orphan Therapeutics, Inc. 2016 Equity Incentive Plan (filed herewith)](ex99-1.htm) |
| 99.2 | [Jupiter Orphan Therapeutics, Inc. 2021 Equity Incentive Plan (filed as Exhibit 10.1 to the Company's Registration Statement on Form S-1 filed with the SEC on October 12, 2021)](https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-1.htm) |
| 99.3 | [Jupiter Neurosciences, Inc. 2023 Equity Incentive Plan (filed as Exhibit 10.40 to the Company's Registration Statement on Form S-1/A filed with the SEC on July 12, 2024)](https://www.sec.gov/Archives/edgar/data/1679628/000149315224027145/ex10-40.htm) |
| 99.3 | [Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on December 22, 2025)](https://www.sec.gov/Archives/edgar/data/1679628/000149315225028789/ex10-1.htm) |
| 107 | [Filing Fee Table (filed herewith).](ex107.htm) |

---

---

| | |
|:---|:---|
| **ITEM 9.** | **UNDERTAKINGS** |

---

(a) *Rule 415 offering.* 

The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;1. To
 file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. To
 include any prospectus required by Section 10(a)(3) of the Securities Act;

ii. To
 reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
 post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
 forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
 the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
 of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if,
 in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth
 in the "Calculation of Registration Fee" table in the effective registration statement.

iii. To
 include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement
 or any material change to such information in the registration statement;

*Provided however*, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;2. That,
 for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a
 new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be
 deemed to be the initial bona fide offering thereof.

3. To
 remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
 termination of the offering.

(b) The
 undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of
 the registrant's annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each
 filing of an employee benefit plan's annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference
 in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and
 the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar
 as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
 of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the
 SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
 that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid
 by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted
 by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in
 the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
 question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the
 final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jupiter, Florida on February 13, 2026.

---

| | |
|:---|:---|
| **JUPITER NEUROSCIENCES, INC.** | **JUPITER NEUROSCIENCES, INC.** |
| By: | */s/ Christer Rosén* |
|  | Christer Rosén |
|  | Chairman of the Board and Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Christer Rosén as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Christer Rosén* | Chairman of the Board and Chief Executive Officer |  |
| Christer Rosén | (*Principal Executive Officer*) | February 13, 2026 |
| */s/ Saleem Elmasri* | Chief Financial Officer |  |
| Saleem Elmasri | (*Principal Financial and Accounting Officer*) | February 13, 2026 |
| */s/ Marshall Hayward, Ph.D* |  |  |
| Marshall Hayward, Ph.D. | Director | February 13, 2026 |
| */s/ Alison D. Silva* |  |  |
| Alison D. Silva | Director | February 13, 2026 |
| */s/ Nicholas H. Hemmerly* |  |  |
| Nicholas H. Hemmerly | Director | February 13, 2026 |
| */s/ Julie Kampf* |  |  |
| Julie Kampf | Director | February 13, 2026 |
| */s/ Allison W. Brady* |  |  |
| Allison W. Brady | Director | February 13, 2026 |
| */s/ Holger Weis* |  |  |
| Holger Weis | Director | February 13, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](ex5-1_001.jpg) | Reed Smith LLP<br> Reed Smith Centre<br> Pittsburgh, PA 15222-2716<br> +1 412 288 3131<br> Fax +1 412 288 3063<br> reedsmith.com |

---

February 13, 2026

1001 North US HWY 1, Suite 504

Jupiter, Florida 33477

Ladies and Gentlemen:

We have acted as counsel to Jupiter Neurosciences, Inc., a Delaware corporation (the "**Company**"), in connection with the Registration Statement on Form S-8 (the "**Registration Statement**") filed by the Company with the Securities and Exchange Commission (the "**Commission**") under the Securities Act of 1933, as amended (the "**Securities Act**"), relating to the offer and sale by the Company of up to 15,700,464 shares of common stock, par value $0.0001 per share of the Company (the "**Shares**"), including (i) 6,167,679 Shares reserved for issuance upon the exercise of outstanding options granted under the Jupiter Orphan Therapeutics, Inc. 2016 Equity Incentive Plan (the "**2016 Plan**"), (ii) 270,000 Shares reserved for issuance upon the exercise of outstanding options granted under the Jupiter Orphan Therapeutics, Inc. 2021 Equity Incentive Plan (the "**2021 Plan**"), (iii) 1,339,605 Shares reserved for issuance upon the exercise of outstanding options granted under the Jupiter Neurosciences, Inc. 2023 Equity Incentive Plan (the "**2023 Plan**"), (iv) 1,626,045 Shares reserved for issuance for outstanding restricted stock units granted under the 2023 Plan, (v) 1,047,135 Shares reserved for issuance under the 2023 Plan, and (vi) 5,250,000 Shares reserved for issuance under the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan (the "**2025 Plan**", and together with the 2016 Plan, the 2021 Plan, and the 2023 Plan, the "**Plans**"). This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

We have reviewed originals or copies of the Registration Statement, the Certificate of Incorporation and Amended and Restated By-Laws of the Company, as amended through the date hereof, and such other corporate records, agreements and documents of the Company, certificates or comparable documents of public officials and officers of the Company and have made such other investigations as we have deemed necessary as a basis for the opinion set forth below.

In rendering the opinion set forth below, we have assumed:

&nbsp;&nbsp;&nbsp;&nbsp;a. the
 genuineness of all signatures;

&nbsp;&nbsp;&nbsp;&nbsp;b. the
 legal capacity of natural persons;

&nbsp;&nbsp;&nbsp;&nbsp;c. the
 authenticity of all documents submitted to us as originals;

&nbsp;&nbsp;&nbsp;&nbsp;d. the
 conformity to original documents of all documents submitted to us as duplicates or conformed copies;

&nbsp;&nbsp;&nbsp;&nbsp;e. as
 to matters of fact, the truthfulness of the representations made in certificates or comparable documents of public officials and
 officers of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;f. the
 board of directors of the Company or a duly constituted and acting committee of such board of directors will have taken all action
 necessary to set the public offering price of the Shares;

&nbsp;&nbsp;&nbsp;&nbsp;g. with
 respect to the issuance of the Shares, the amount of valid consideration paid in respect of such Shares will equal or exceed the
 par value of such Shares; and

h. that
 there are no agreements or understandings between or among the Company and any participants in the Plans that would expand, modify
 or otherwise affect the terms of the Plans or the respective rights or obligations of any participants thereunder.

We have not independently established the validity of the foregoing assumptions.

Based upon the foregoing, and subject to the qualifications, assumptions and limitations stated herein, we are of the opinion that, when the Shares are issued and sold by the Company in the manner contemplated in the Registration Statement against payment therefor in the circumstances contemplated by the Plans and assuming that the individual issuances, grants or awards under the Plans are duly authorized by all necessary corporate action of the Company and duly issued, granted or awarded and exercised and paid for, for consideration at least equal to the par value thereof, in accordance with the requirements of law and the Plans (and the agreements and awards either duly adopted thereunder and in accordance therewith), the offer and sale of the Shares shall have been duly authorized and, when and to the extent that the Shares are issued in accordance with the foregoing, the Shares will be validly issued, fully paid and nonassessable.

Our opinion is limited to the General Corporation Law of the State of Delaware and we do not express any opinion herein concerning any other law. This opinion letter speaks only as of its date.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the use of our name therein. In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, and the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

/s/ Reed Smith LLP

REED SMITH LLP

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Jupiter Neurosciences, Inc. of our report dated March 28, 2025, relating to our audit of the financial statements as of December 31, 2024 and 2023 and for the years ended December 31, 2024 and 2023, which appears in the Registration Statement on Form S-1 of Jupiter Neurosciences, Inc. for the years then ended.

We also consent to the reference to our firm under the caption "Experts" in the Prospectus, which is part of this Registration Statement.

![](ex23-1_001.jpg)

Assurance Dimensions

Coral Springs, Florida

February 13, 2026

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

![](ex99-1_002.jpg)

![](ex99-1_003.jpg)

![](ex99-1_004.jpg)

![](ex99-1_005.jpg)

![](ex99-1_006.jpg)

![](ex99-1_007.jpg)

![](ex99-1_008.jpg)

![](ex99-1_009.jpg)

![](ex99-1_010.jpg)

![](ex99-1_011.jpg)

![](ex99-1_012.jpg)

![](ex99-1_013.jpg)

![](ex99-1_014.jpg)

![](ex99-1_015.jpg)

![](ex99-1_016.jpg)

![](ex99-1_017.jpg)

![](ex99-1_018.jpg)

![](ex99-1_019.jpg)

![](ex99-1_020.jpg)

![](ex99-1_021.jpg)

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Jupiter Neurosciences, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security**<br> **Type** | **Security Class Title** | **Fee**<br> **Calculation** | **Amount**<br> **Registered(1)** |  | **Proposed**<br> **Maximum**<br> **Offering**<br> **Price Per Unit** |  | **Maximum**<br> **Aggregate Offering**<br> **Price**  | **Fee Rate** | **Amount of**<br> **Registration Fee** |
| Fees to Be Paid | Equity | Common stock, $0.0001 par value per share | Other | 6167679 | (2) | $0.80 | (3) | $4934143.20 | 0.0001381 | $681.41 |
| Fees to Be Paid | Equity | Common stock, $0.0001 par value per share | Other | 270000 | (4) | $1.33 | (5) | $359100.00 | 0.0001381 | $49.59 |
| Fees to Be Paid | Equity | Common stock, $0.0001 par value per share | Other | 1339605 | (6) | $1.13 | (7) | $1513753.65 | 0.0001381 | $209.05 |
| Fees to Be Paid | Equity | Common stock, $0.0001 par value per share | Other | 1626045 | (8) | $.6053 | (9) | $984245.04 | 0.0001381 | $135.92 |
| Fees to Be Paid | Equity | Common stock, $0.0001 par value per share | Other | 1047135 | (10) | $.6053 | (11) | $633830.82 | 0.0001381 | $87.53 |
| Fees to Be Paid | Equity | Common stock, $0.0001 par value per share | Other | 5250000 | (12) | $.6053 | (13) | $3177825.00 | 0.0001381 | $438.86 |
|  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  |  | $11602897.71 |  | $1602.36 |
|  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid |  |  |  |  |  |
|  | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |  |
|  | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  |  | $1602.36 |

---

(1) Pursuant
 to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"),
 this registration statement shall also cover any additional shares of the Registrant's
 Common Stock that become issuable under the Jupiter Orphan Therapeutics, Inc. 2016 Equity
 Incentive Plan (the "2016 Plan"), the Jupiter Orphan Therapeutics, Inc. 2021
 Equity Incentive Plan (the 2021 Plan"), the Jupiter Neurosciences, Inc. 2023 Equity
 Incentive Plan (the "2023 Plan"), and the Jupiter Neurosciences, Inc. 2025 Equity
 Incentive Plan (the "2025 Plan") by reason of any stock dividend, stock split,
 recapitalization or similar transaction effected without the Registrant's receipt of
 consideration which would increase the number of outstanding shares of common stock.

(2) Represents
 shares of Common Stock reserved for issuance upon the exercise of outstanding options granted
 under the 2016 Plan.

(3) Estimated
 solely for the purpose of calculating the registration fee pursuant to Rule 457(h) under
 the Securities Act, and based upon a price of $0.80 per share, which is the weighted-average
 exercise price for options outstanding under the 2016 Plan.

(4) Represents
 shares of Common Stock reserved for issuance upon the exercise of outstanding options granted
 under the 2021 Plan.

(5) Estimated
 solely for the purpose of calculating the registration fee pursuant to Rule 457(h) under
 the Securities Act, and based upon a price of $1.33 per share, which is the weighted-average
 exercise price for options outstanding under the 2021 Plan.

(6) Represents
 shares of Common Stock reserved for issuance upon the exercise of outstanding options granted
 under the 2023 Plan.

(7) Estimated
 solely for the purpose of calculating the registration fee pursuant to Rule 457(h) under
 the Securities Act, and based upon a price of $1.13 per share, which is the weighted-average
 exercise price for options outstanding under the 2023 Plan.

(8) Represents shares of Common
 Stock reserved for issuance for outstanding restricted stock units granted under the 2023 Plan.

(9) Estimated solely for purposes
 of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act. The proposed maximum offering price
 per share and the maximum aggregate offering price are based on a price of $.6053 per share, which is the average of the high and low
 prices of the Registrant's Common Stock, as reported on the Nasdaq Capital Market, on February 10, 2026.

(10) Represents shares of Common
 Stock reserved for issuance under the 2023 Plan.

(11) Estimated solely for purposes
 of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act. The proposed maximum offering price
 per share and the maximum aggregate offering price are based on a price of $.6053 per share, which is the average of the high and low
 prices of the Registrant's Common Stock, as reported on the Nasdaq Capital Market, on February 10, 2026.

(12) Represents shares of Common
 Stock reserved for issuance under the 2025 Plan.

(13) Estimated solely for purposes
 of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act. The proposed maximum offering price
 per share and the maximum aggregate offering price are based on a price of $.6053 per share, which is the average of the high and low
 prices of the Registrant's Common Stock, as reported on the Nasdaq Capital Market, on February 10, 2026.

N/A